| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

13 October 2021

ORYZON presents safety and efficacy data of vafidemstat from the Phase II SATEEN trial in multiple sclerosis at ECTRIMS-2021

22-23 October 2021

2021 Virtual Kabuki Syndrome Foundation Annual Conference

13-15 October 2021

37th Congress of the European Committe for Treatment and Research in Multiple Sclerosis. ECTRIMS 2021

2-5 October 2021

34th European College Neuropsychopharmacology (ECNP) congress 2021

27 September - 1 October 2021

BIO-Spain 2021

23-24 September 2021

International Conference on Autism ICA-2021

22 September 2021

ORYZON to present new clinical data and corporate updates at international conferences in September and October

21 September 2021

Oryzon announces $1 million grant from Kabuki syndrome philanthropists to support a precision medicine Phase I/II trial with vafidemstat

29 July 2021

ORYZON reports results and corporate update for first half ended June 30, 2021

13 July 2021

ORYZON receives approval to start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia

Pagination

First page «
Previous page ‹
Page 20
Page 21
Page 22
Page 23
Current page 24
Page 25
Page 26
Page 27
Page 28
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel